在接受冠状动脉手术的患者中,trimetazidine对功能的影响
Yasser Abdel-Hady1, Mohammed Taha2, Ahmed El Barbary2
1Cardiology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
BMC pharmacology & toxicology
|April 16, 2025
概括
在冠状动脉手术后72小时内,三甲 (TMZ) 并没有强有力的预防对比诱导性病 (CIN). 然而,TMZ在慢性冠状动脉综合征患者的手术后一个月显示出潜在的适度,长期的益.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 对比诱导性病 (CIN) 是通过皮肤冠状动脉干预 (PCI) 或冠状动脉血管学 (CA) 后的一种风险.
- 三甲素 (TMZ) 呈现出抗胰岛症,抗氧化剂和线粒体保护作用,被研究用于预防CIN.
- 指导医学疗法 (GDMT) 是接受冠状动脉手术的患者的标准护理.
研究的目的:
- 评估三甲 (TMZ) 添加到指导医疗治疗指南 (GDMT) 的脏保护作用.
- 评估TMZ对对比诱导性病 (CIN) 和冠状动脉手术后功能发展的影响.
主要方法:
- 一项前性观察队列研究,涉及410名慢性冠状动脉综合征 (CCS) 患者.
- 第一组 (205名患者) 接受了GDMT加TMZ;第二组 (205名患者) 仅接受了GDMT.
- 主要终点:72小时后CIN的发展. 二级终点:在一个月的随访后,功能.
主要成果:
- 72小时后的CIN率在TMZ组为13.2%,对照组为22.0% (FDR调整后p=0.047).
- 一个月后的CIN率在TMZ组为6.3%,对照组为13.2% (FDR调整后p=0.050).
- 结果表明TMZ具有适度的保护作用,特别是在长期的益方面.
结论:
- 在这个队列中,trimetazidine (TMZ) 在72小时内没有显示出对CIN的强有力的保护.
- 在手术后一个月,TMZ可能会提供适度的,临床相关的,长期的益.
- 需要进一步的随机试验来确认TMZ的疗效,并阐明其在CIN预防中的机制.
相关概念视频
Renal Failure: Dose Adjustments
35
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
35
Antihypertensive Drugs: Thiazide-Class Diuretics
443
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
443
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
691
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
691
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
315
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
315
Heart Failure Drugs: Diuretics
287
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
287
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K


